Troy Jensen

Alexander Craeymeersch

Jacob Stephan

- Materialise reported **consolidated revenue of €66.3 million** for Q3 2025, representing a **3.5% decrease** compared to Q3 2024, though it grew 2% compared to Q2 2025.  **[0001091223_2207875_4]** 
- The **Medical segment achieved an all-time revenue record of €33.3 million**, growing **over 10%** year-over-year, while the Software and Manufacturing segments experienced declines of **7%** and **17%**, respectively, primarily due to macroeconomic headwinds.  **[0001091223_2207875_4]** 
- The company's **gross profit margin remained strong at 56.8%** in Q3 2025, and **adjusted EBIT amounted to €2.9 million** (4.4% of revenue), leading to a **net profit of €1.8 million**.  **[0001091223_2207875_4]** 
- Materialise's **net cash position increased to €67.7 million**, driven by strong free cash flow during the quarter.  **[0001091223_2207875_4]** **[0001091223_2207875_6]** 
- The company **maintained its full-year 2025 guidance**, expecting revenues in the range of **€265 to €280 million** and adjusted EBIT between **€6 and €10 million**.  **[0001091223_2207875_7]**

Materialise Reports Q3 2025 Financial Results

- **Materialise** reported **Q3 2025 revenue** of **66.3 mEUR**, a **3.5% decrease** from Q3 2024, with **net profit** at **1.8 mEUR** or **0.03 EUR per share**.  **[0001091223_2207613:5]** **[0001091223_2207613:7]** 
- **Adjusted EBIT** for Q3 2025 was **2.9 mEUR**, representing **4.4% of revenue** and a **34% decrease** compared to Q3 2024, while **Adjusted EBITDA** decreased **15%** to **8.4 mEUR**.  **[0001091223_2207613:5]** **[0001091223_2207613:6]** 
- The **Medical segment** saw revenue increase **10.3%** to **33.3 mEUR**, but the **Software** and **Manufacturing segments** experienced revenue decreases of **7%** and **17%** respectively, partly due to macro-economic headwinds.  **[0001091223_2207613:5]** **[0001091223_2207613:6]** 
- The company's **net cash position** increased by **6.7 mEUR** from year-end 2024 to **67.7 mEUR** at the end of Q3 2025.  **[0001091223_2207613:5]** 
- **Materialise** is maintaining its **2025 financial guidance**, expecting consolidated revenue between **265 - 280 mEUR** and consolidated Adjusted EBIT between **6 - 10 mEUR**.  **[0001091223_2207613:8]**

Materialise Announces Q3 2025 Financial Results

- Materialise's **consolidated revenue** for Q3 2025 was **EUR 66.3 million**, representing a **3.5% decrease** compared to Q3 2024, though it grew by **2%** from Q2 2025.  **[0001091223_2210026_4]** 
- The **Materialise Medical** segment achieved a record revenue of **EUR 33.3 million**, growing by **over 10%** year-over-year, while the **Software** and **Manufacturing** segments experienced declines of **7%** and **17%**, respectively, impacted by macroeconomic headwinds.  **[0001091223_2210026_4]** 
- **Adjusted EBIT** for the third quarter of 2025 amounted to **EUR 2.9 million**, resulting in a **4.4% margin**, and the company generated a **net profit of EUR 1.8 million**.  **[0001091223_2210026_4]** 
- The company's **net cash position** further increased to **EUR 67.7 million** at the end of Q3 2025.  **[0001091223_2210026_4]** **[0001091223_2210026_6]** 
- Materialise **maintained its full-year 2025 guidance**, expecting revenues in the range of **EUR 265 million to EUR 280 million** and adjusted EBIT between **EUR 6 million and EUR 10 million**.  **[0001091223_2210026_7]**

- Materialise NV's total consolidated revenue for the third quarter of 2025 decreased **3.5%** to **66,259 kEUR** compared to the third quarter of 2024.  **[1091223_0001104659-25-102864_tm2529582d1_ex99-1.htm:1]** **[1091223_0001104659-25-102864_tm2529582d1_ex99-1.htm:5]** 
- Net profit for Q3 2025 was **1,848 kEUR**, or **0.03 EUR per diluted share**.  **[1091223_0001104659-25-102864_tm2529582d1_ex99-1.htm:1]** **[1091223_0001104659-25-102864_tm2529582d1_ex99-1.htm:5]** 
- Revenue from the Materialise Medical segment grew **10.3%** to **33,296 kEUR** in Q3 2025, while the Materialise Manufacturing segment's revenue decreased **17.1%** to **22,677 kEUR**.  **[1091223_0001104659-25-102864_tm2529582d1_ex99-1.htm:1]** **[1091223_0001104659-25-102864_tm2529582d1_ex99-1.htm:9]** 
- The company's net cash position increased by **6,724 kEUR** to **67,744 kEUR** as of September 30, 2025, compared to December 31, 2024.  **[1091223_0001104659-25-102864_tm2529582d1_ex99-1.htm:1]** **[1091223_0001104659-25-102864_tm2529582d1_ex99-1.htm:2]** 
- Materialise maintained its full-year 2025 guidance, expecting revenues between **265,000 kEUR and 280,000 kEUR** and Adjusted EBIT between **6,000 kEUR and 10,000 kEUR**.  **[1091223_0001104659-25-102864_tm2529582d1_ex99-1.htm:2]**

MATERIALISE (MTLS)